University of Montana — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ambrisentan and theophyllineThis study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.	SEP	Phase 2/3	Traitement symptomatique	United States	À vérifier
ambrisentan and theophyllineThis study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.	SEP	Phase 2/3	Traitement symptomatique	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
ambrisentan and theophylline	SEP	Phase 2/3	NCT01902758	Drug Combination on Exercise Performance at High Altitude	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.